On April 20, 2026, DarioHealth Corp. (DRIO:NASDAQ) announced the publication of a study demonstrating improved workplace function and productivity due to its digital behavioral health program. The real-world study, peer-reviewed and published in JMIR Formative Research, is titled "Enhancing Workplace Outcomes Through Digital Behavioral Health Programs: Retrospective Real–World Study" and was authored by Inbar Breuer Asher, David L. Horwitz, Omar Manejwala, and Yifat Fundoiano-Herschovitz and follows 1,254 users dealing with concentration difficulties in the workplace. The digital health platform integrates behavioral health with cardiometabolic support, addressing issues such as diabetes, hypertension, weight management, musculoskeletal issues, and behavioral health struggles.
The study claims that significant improvements appeared within the first six weeks, with even better efficacy by week 10, and found comparable results for procrastination and work-based mistakes.
Yifat Hershcovitz, Ph.D., and Vice President of Clinical and Scientific Affairs at DarioHealth, said in the release, "These findings further validate Dario's approach of combining behavioral science, data-driven insights, and continuous engagement to help people develop sustainable habits that improve everyday functioning and health outcomes."
DarioHealth Corp. is an American digital health company headquartered in New York City. The company is focused on helping people manage health during chronic illness via its digital health platform. In partnerships with other companies, DarioHealth also works in the GLP-1, fall prevention, sleep apnea, maternal health, and direct care sectors.
The Psychosocial & Work-Related Illness Sector
"A growing occupational epidemiology literature, including many prospective cohort studies, has investigated the role of psychosocial work stressors on mental health problems and chronic physical illnesses (e.g., CVD and CVD-related risks) in working populations. Work stressors have also been shown to affect chronic illnesses indirectly by influencing health behaviors, including leisure time physical activity, smoking, and alcohol consumption, all of which are considered risk factors for obesity, diabetes, and heart disease," according to a report by Marnie Dobson, Peter Snall, Ellen Rosskam, and Paul Landsbergis. The authors went on to say that ". . . 5-8% of health-care costs in the USA could be attributed to workplace stressors" and that ". . . around 20–40% of all sickness absence can be explained by psychosocial factors."
A report by Bruce Y. Lee, MD and MBA, Professor of Health Policy and Management at CUNY Graduate School of Public Health and Health Policy asserted that, "Employee disengagement, overextension, ineffectiveness, and burnout over the course 64 of one year costs an employer an average of US$3,999 (95% range: US$3,958-US$4,299) for an average 65 U.S. non-managerial hourly employee, an average of US$4,257 (95% range: US$4,215-US$4,299) for an 66 average non-managerial salaried employee, US$10,824 (95% range: US$10,700-US$10,948) for an 67 average manager, and US$20,683 (95% range: US$20,451-US$20,915) for an average executive."
According to DarioHealth's news release, "For employers, the stakes [of behavioral issues in the workplace are significant: illness-related lost productivity — including absenteeism and reduced on-the-job performance (i.e., presenteeism) — costs U.S. employers an estimated US$575 billion annually. This highlights the need for scalable solutions like Dario that help employees manage health challenges while maintaining daily functioning at work."
New Research Swaying Analysts
According to FactSet:
- On March 19, 2026, CG Capital gave DarioHealth a 'Buy' rating, with a US$28 target price.
- On March 19, 2026, Sifel Nicolaus analyst David Grossman gave DarioHealth a 'Buy' rating, with a US$10 target price.
- On April 9, 2026, TD Cowen analyst Charles Rhyee gave DarioHealth a 'Hold' rating, with a US$11 target price.
On April 27, 2026, Ashok Kumar, Ph.D. and CFA, wrote a research report on DarioHealth for Think Equity.
Kumar gave the company a 'Buy' rating, with a price target of US$25, writing, "Our variant view is narrow. We do not assume a dramatic breakout, explicit takeout value, or unsupported AI monetization. We assume partial conversion of disclosed commercial activity, continued mix improvement, and cost discipline . . . The shares remain speculative, but the reported facts support BUY and the unchanged US$25.00 target. That is the right balance for a still-funding-dependent small-cap platform today."
Streetwise Ownership Overview*Investors are Intrigued
DarioHealth's investor presentation lists new contracts and expanding market access as catalysts for investment. The company states that 70% of new contracts are multi-condition, which allows vendors to consolidate programs for better ROI and savings.
The company also claims a US$122 million pipeline of commercial opportunities, which it says is accelerating sales and enabling rapid onboarding of large employers and health plans.
Ownership & Share Information1
DarioHealth Corp. has a market cap of US$54.17 million, with 7.30 million shares outstanding.
The company's 52-week range is US$5.94-US$17.74.
Institutions own 10.53% of shares, while Strategic Investors own 9.88%.
Management & Insiders own 11.24% of shares, and the remaining 68.35% of shares are held by Retail.
| Want to be the first to know about interesting Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
